Disease Landscape and Forecast Insights

The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.)…

The hepatocellular carcinoma therapy market is experiencing substantial growth. Angiogenesis inhibitors have played a central role in treating advanced disease, and immunotherapies such as Roche’…

Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-…

The treatment landscape for endometrial carcinoma is rapidly evolving, driven by the growing adoption of immune checkpoint inhibitors and advancements in molecular classification. Although…

The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…

The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche /…

Clarivate Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts of key breast cancer patient populations, covering 171 countries and more…

Clarivate Epidemiology’s coverage of breast cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of breast…

Clarivate Epidemiology’s coverage of breast cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of breast…

Clarivate Epidemiology’s coverage of malignant pleural mesothelioma (MPM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…